fire-3 study: cetuximab versus bevacizumab in metastatic colorectal cancer
Published 10 years ago • 1.9K plays • Length 4:16Download video MP4
Download video MP3
Similar videos
-
4:28
introduction: bevacizumab versus cetuximab in metastatic colorectal cancer
-
4:56
upfront bevacizumab and cetuximab compared in metastatic colorectal cancer
-
3:45
fire-3: cetuximab/folfiri prolongs metastatic colorectal cancer survival
-
4:25
fire-4.5: folfoxiri plus either bevacizumab or cetuximab in mcrc
-
3:01
deeper: m-folfoxiri and cetuximab versus bevacizumab in mcrc
-
0:37
dr. volker heinemann reviews the fire-3 trial results
-
6:19
clinical development of cetuximab in metastatic colorectal cancer
-
3:59
asco 2013: cetuximab superior to bevacizumab for advanced colorectal cancer
-
8:41
calgb 80405 trial results in metastatic colorectal cancer
-
10:30
debate 1: first-line treatment of metastatic colorectal cancer - fire-3
-
11:15
bevacizumab and cetuximab (plus chemotherapy) equally effective for colorectal cancer patients
-
7:46
a closer look at fire-3 and calgb/swog 80405
-
1:08
dr. weinberg on the role of cetuximab in metastatic crc
-
9:02
bevacizumab and cetuximab (plus chemotherapy) equally effective for colorectal cancer patients
-
2:45
1l folfoxiri plus cetuximab or bevacizumab for ras wild-type mcrc
-
1:24
fire-4.5: folfoxiri plus either bevacizumab or cetuximab as 1l treatment of braf v600e-mutant mcrc
-
1:59
bevacizumab and cetuximab (plus chemo) have similar benefits in metastatic colorectal cancer
-
2:42
dr. bekaii-saab discusses an analysis of bevacizumab or cetuximab for crc
-
8:16
beacon crc: first-line bevacizumab in colorectal cancer treatment